Actinium Pharmaceuticals, Inc. (ATNM)

Negative net income growth while Biotechnology median is 0.00%. Seth Klarman would suspect a firm-specific problem if peers maintain profit growth.

D&A shrinks yoy while Biotechnology median is 0.00%. Seth Klarman would see a short-term earnings benefit if capacity is sufficient.

SBC declines yoy while Biotechnology median is 0.00%. Seth Klarman would see a near-term advantage in less dilution unless new hires are needed.

Under 50% of Biotechnology median of 6.50% or exceeding it in the negative sense. Jim Chanos would suspect a bigger working capital drain if growth is not justified by sales.

AP growth of 478.18% while Biotechnology median is zero at 0.00%. Walter Schloss would question expansions or credit policies affecting the difference.

Growth of 8.45% while Biotechnology median is zero at 0.00%. Walter Schloss would question expansions or unusual one-time factors behind the difference.

Other non-cash items dropping yoy while Biotechnology median is -9.52%. Seth Klarman would see a short-term advantage if real fundamentals remain intact.

Negative CFO growth while Biotechnology median is 2.12%. Seth Klarman would suspect a firm-specific operational weakness if peers maintain growth.

CapEx growth of 100.00% while Biotechnology median is zero at 0.00%. Walter Schloss would question expansions or upgrades behind the difference.

No Data available this quarter, please select a different quarter.

Investing flow of 100.00% while Biotechnology median is zero at 0.00%. Walter Schloss would question expansions or deals prompting that difference.

Debt repayment yoy declines while Biotechnology median is 0.00%. Seth Klarman fears increased leverage if expansions do not yield quick returns.

We reduce issuance yoy while Biotechnology median is 0.00%. Seth Klarman might see an advantage in preserving per-share value unless expansions are neglected.

No Data available this quarter, please select a different quarter.